Original Research

Page 4

Recently published articles about Original Research

PCC
The Patient in the Mirror
Original Research

The Patient in the Mirror

June 11, 2026

The authors describe the unique challenges physicians may experience when they become patients and examine common physician-as-patient themes portrayed in media, including implications for clinical practice and medical education.
, , , et al
JCP
Hallucinogen–Psychosis Associations Are Confounded by Baseline Psychiatric History
Original Research ▶ Video

Hallucinogen–Psychosis Associations Are Confounded by Baseline Psychiatric History

June 10, 2026

Apparent associations between hallucinogen use and psychosis appear largely attributable to baseline psychiatric comorbidities rather than direct causal effects.
, , , et al
PCC
Prevalence of Anxiety in an Underserved Population
Original Research

Prevalence of Anxiety in an Underserved Population

June 9, 2026

Generalized anxiety disorder is highly prevalent in underserved Venezuelan populations, particularly among women, highlighting the need for routine screening in primary care settings.
, , , et al
JCP
County-Level Variation in Substance Use Disorder Service Utilization by Insurance Payers and Self-Pay
Original Research ▶ Video

County-Level Variation in Substance Use Disorder Service Utilization by Insurance Payers and Self-Pay

June 8, 2026

Across all examined payers, Medicaid funded a disproportionate share—over 50%—of SUD service expenditures.
, , , et al
JCP
Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression
Original Research

Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression

June 3, 2026

Mebufotenin (GH001) demonstrated rapid and significant improvements in depressive symptoms and remission of postpartum depression.
, , , et al
PCC
Global Research Trends in Community Psychiatry
Original Research

Global Research Trends in Community Psychiatry

June 2, 2026

This bibliometric analysis identifies the practice-relevant areas most emphasized in the “community psychiatry” literature (2015–2025), which clinicians can use to prioritize local quality improvement targets aligned with current service...
, ,
JCP
Viloxazine ER in Adults With ADHD and Depression and/or Anxiety Symptoms
Original Research

Viloxazine ER in Adults With ADHD and Depression and/or Anxiety Symptoms

May 27, 2026

Viloxazine ER was well tolerated and associated with improvements in ADHD, depression, and anxiety symptoms in this real-world study.
, , , et al
PCC
Lorazepam vs. Diazepam in AUD
Original Research

Lorazepam vs. Diazepam in AUD

May 26, 2026

Both lorazepam and diazepam led to more than 50% reduction in Clinical Institute Withdrawal Assessment for Alcohol–Revised scores within 5 days of initiation of treatment in alcohol dependence syndrome.
, , , et al
JCP
National Trends in PTSD among US Military Veterans
Original Research

National Trends in PTSD among US Military Veterans

May 25, 2026

Compared with 2019–2020, past-month PTSD prevalence was higher among men, White and racial/ethnic minority veterans, and veterans aged 18–59 years
, , , et al
JCP
Effect of a Nationwide Aftercare Program for Self-Harm Presentations on the Risk of Self-Harm Repetition and Suicide
Original Research

Effect of a Nationwide Aftercare Program for Self-Harm Presentations on the Risk of Self-Harm Repetition and Suicide

May 20, 2026

Aftercare following self-harm was associated with increased risk of repeat self-harm hospital presentation and decreased risk of suicide.
, , , et al
JCP
Differential Impact of Cholecystokinin and Ghrelin on 2-Year Avoidant/Restrictive Food Intake Disorder Symptoms
Original Research

Differential Impact of Cholecystokinin and Ghrelin on 2-Year Avoidant/Restrictive Food Intake Disorder Symptoms

May 20, 2026

Decreases in CCK and increases in ghrelin were associated with improvements in ARFID symptomology.
, , , et al
JCP
NNT, NNH, and LLH for Aripiprazole Once-Monthly in Schizophrenia
Original Research

NNT, NNH, and LLH for Aripiprazole Once-Monthly in Schizophrenia

May 13, 2026

Data demonstrate a favorable benefit-risk profile for aripiprazole once-monthly 400 vs placebo in acute and maintenance treatment of schizophrenia.
, , , et al

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe